Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy.

ABSTRACT:

Aims

The 8th Edition of the American Joint Committee on Cancer Staging System (yAJCC) excludes treatment-related fibrosis from the measurement of residual tumour after neoadjuvant chemotherapy (NAC) for breast cancer. The impact of the 8th Ed. yAJCC on post-NAC pathologic staging was examined in 188 breast cancer specimens from 183 patients with measurable residual tumour.

Methods

Tumour size, ypT, and ypN categories were reassessed with the current yACC criteria and compared to the original pathology reports. Histological patterns of response in the breast were categorised as concentric or scattered.

Results

The reassessed breast tumour size or ypT category differed from the original report in 101 (53.7%) cases. Changes in the ypT and/or ypN category resulted in down

SUBMITTER: Harter D 

PROVIDER: S-EPMC10524558 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature